Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Diplomat Pharmacy selected to distribute Novartis' COSENTYX (secukinumab)

Diplomat Pharmacy selected to distribute Novartis' COSENTYX (secukinumab)

Key questions about colorectal cancer answered

Key questions about colorectal cancer answered

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Reslizumab drug appears to reduce risk of severe asthma attacks

Reslizumab drug appears to reduce risk of severe asthma attacks

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre predicts ranibizumab vision improvement

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

Researchers study epidemiology of Ebola Virus Disease to prevent future disease outbreaks

Researchers study epidemiology of Ebola Virus Disease to prevent future disease outbreaks

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.